Columbia Laboratories to Discuss Third Quarter 2006 Financial Results on November 9, 2006 Conference Call.LIVINGSTON, N.J. -- Columbia Laboratories, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : CBRX) will hold a conference call on November 9, 2006, to review and discuss financial results of the third quarter and nine months ended September 30, 2006. Robert Mills, Columbia's president and chief executive officer, and David Weinberg, chief financial officer, will host the call. Access information Date: Thursday, November 9, 2006 Time: 11:00 AM ET U.S./Canada dial-in number: (800) 753-0420 International dial-in number: (913) 981-5554 Participant passcode: 8564426 Live webcast: www.columbialabs.com Replay Access Information A recording of the conference call will be available two hours after completion until November 15, 2006 at 11:59 PM ET at (888) 203-1112 (U.S.) and (719) 457-0820 (International). The replay passcode is 8564426. The webcast will be archived for on-demand listening for one year on Columbia Laboratories' website, www.columbialabs.com, under "Events" in the Investor section. About Columbia Laboratories, Inc. Columbia Laboratories, Inc. is a U.S.-based international pharmaceutical company dedicated to the development and commercialization of reproductive healthcare and endocrinology products that use its novel bioadhesive drug delivery technology. Columbia markets PROCHIEVE([R]) 8% (progesterone gel) for progesterone supplementation as part of an Assisted Reproductive Technology Assisted reproductive technology (ART) is a general term referring to methods used to achieve pregnancy by artificial or partially artificial means. It is reproductive technology used in infertility treatment, which is the only application routinely used today of treatment for infertile women with progesterone deficiency and PROCHIEVE([R]) 4% (progesterone gel) for the treatment of secondary amenorrhea. The Company also markets STRIANT([R]) (testosterone buccal buc·cal adj. 1. Of, relating to, adjacent to, or in the direction of the cheek. 2. Of or relating to the mouth cavity. buccal system) for the treatment of hypogonadism Hypogonadism Definition Hypogonadism is the condition more prevalent in males in which the production of sex hormones and germ cells are inadequate. in men. The Company recently completed enrollment in a large-scale pivotal Phase III study to evaluate the possible utility of PROCHIEVE([R]) 8% (progesterone gel) in the prevention of recurrent preterm birth. This randomized ran·dom·ize tr.v. ran·dom·ized, ran·dom·iz·ing, ran·dom·iz·es To make random in arrangement, especially in order to control the variables in an experiment. , double-blind, placebo-controlled trial involves 669 patients at more than 60 centers globally. The Company's additional research and development programs include a vaginally-administered lidocaine lidocaine /li·do·caine/ (li´do-kan) an anesthetic with sedative, analgesic, and cardiac depressant properties, applied topically in the form of the base or hydrochloride salt as a local anesthetic; also used in the latter form as a product to treat dysmenorrhea dysmenorrhea Pain or cramps before or during menstruation. In primary dysmenorrhea, caused by endocrine imbalances, severity varies widely. Irritability, fatigue, backache, or nausea may also occur. . For more information, please visit www.columbialabs.com. PROCHIEVE([R])and STRIANT([R]) are registered trademarks of Columbia Laboratories, Inc. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion